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Background: Polyunsaturated fatty acids (PUFA) have diverse biological effects, from promoting inflammation to
preventing cancer and heart disease. Growing evidence suggests that individual PUFA may have independent
effects in health and disease. The individual roles of the two essential PUFA, linoleic acid (LA) and α-linolenic acid
(ALA), have been difficult to discern from the actions of their highly unsaturated fatty acid (HUFA) downstream
metabolites. This issue has recently been addressed through the development of the Δ-6 desaturase knock out
(D6KO) mouse, which lacks the rate limiting Δ-6 desaturase enzyme and therefore cannot metabolize LA or ALA.
However, a potential confounder in this model is the production of novel Δ-5 desaturase (D5D) derived fatty acids
when D6KO mice are fed diets containing LA and ALA, but void of arachidonic acid.
Objective: The aim of the present study was to characterize how the D6KO model differentially responds to diets
containing the essential n-6 and n-3 PUFA, and whether the direct provision of downstream HUFA can rescue the
phenotype and prevent the production of D5D fatty acids.
Methodology: Liver and serum phospholipid (PL) fatty acid composition was examined in D6KO and wild type
mice fed i) 10% safflower oil diet (SF, LA rich) ii) 10% soy diet (SO, LA+ALA) or iii) 3% menhaden oil +7% SF diet
(MD, HUFA rich) for 28 days (n = 3-7/group).
Results: Novel D5D fatty acids were found in liver PL of D6KO fed SF or SO-fed mice, but differed in the type of D5D
fatty acid depending on diet. Conversely, MD-fed D6KO mice had a liver PL fatty acid profile similar to wild-type mice.
Conclusions: Through careful consideration of the dietary fatty acid composition, and especially the HUFA content in
order to prevent the synthesis of D5D fatty acids, the D6KO model has the potential to elucidate the independent
biological and health effects of the parent n-6 and n-3 fatty acids, LA and ALA.
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Δ6-desaturase (D6D) is the first enzyme in the metabolic
conversion of α-linolenic acid (ALA), an n-3 polyunsat-
urated fatty acid (PUFA), to eicosapentaenoic acid
(EPA), and docosahexaenoic acid (DHA). D6D is also re-
sponsible for initiating the conversion of the n-6 PUFA,
linoleic acid (LA), to arachidonic acid (AA). D6D is
encoded by the FADS2 gene which is present in all* Correspondence: davidma@uoguelph.ca
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reproduction in any medium, provided the ormammals [1] and is most highly expressed in the liver
[2], the main site of PUFA metabolism [3-5]. While
mammals can endogenously produce a limited amount
of AA, EPA and DHA from dietary LA and ALA, mam-
mals do not have the ability to produce LA/ALA en-
dogenously. Thus, both these fatty acids must be
attained solely through dietary means and are considered
essential fatty acids (EFA) [6].
Highly unsaturated fatty acids (HUFA), such as AA,
EPA and DHA are primarily deposited in membrane
phospholipids (PL) as opposed to intracellular triglycer-
ide stores, and contribute to a wide array of cellularal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7], cell signaling, and protein function [8]. Liver phos-
pholipids are differentially enriched in select fatty acids;
phosphatidylcholine (PC) is the main PL and therefore
contains the greatest quantity of fatty acids, while
hepatic phosphatidylinositol (PI) and phosphatidyletha-
nolamine (PE) are enriched in the eicosanoid precursor
AA [9], and lyso-phosphatidylcholine (lyso-PC) is prefer-
entially enriched with DHA for delivery to the brain
[10].Thus, it is of interest to determine the fatty acid
composition of each PL fraction in order to fully explore
the effects of perturbations in essential fatty acid
metabolism.
Select n-6 and n-3 PUFA have garnered attention from
the scientific community and general public for their
roles in the prevention and treatment of lifestyle diseases
such as cardiovascular disease, Type II diabetes and cer-
tain cancers. Many studies [11-13] have aimed to assess
the protective or therapeutic effects of either ALA or LA
through dietary intervention. However, these studies
cannot attribute results directly to either ALA or LA as
there is always some conversion to more highly unsatur-
ated fatty acids (HUFA), such as AA, EPA and DHA.
Thus, any outcomes observed in such studies could also
be due to the effects of AA, EPA and DHA which are all
considered biologically active metabolites. Similarly,
studies aiming to determine the effects of restricting a
particular HUFA such as DHA or AA have not been
able to do so without simultaneous removal of ALA or
LA from the diet [14,15]. A model in which the metabol-
ism of ALA/LA is inhibited would then be of great util-
ity in determining if LA and ALA are independently
able to prevent or alleviate disease.
This hurdle has recently been addressed with the de-
velopment of the novel Δ-6 desaturase knock out
(D6KO) mouse [16,17]. The homozygous D6KO mouse
lacks a functional copy of the FADS2 gene, and is there-
fore unable to produce the D6D protein (Figure 1). This
renders the D6KO mouse completely deficient in EPA/
DHA/AA if these HUFA are not provided in the diet,
since no alternative pathway for the production of these
long chain fatty acids exists.
Previous studies with the D6KO mouse have focused
on the effects of HUFA restriction through the provision
of LA and ALA-enriched soybean oil on macrophage ac-
tivity [18], dermatitis, and intestinal ulceration [17]. In
contrast, the effects of a diet enriched only in LA on
PUFA metabolism and HUFA synthesis in the D6KO
mouse are currently unknown. Dietary studies have also
been carried out on D6KO mice using diets enriched
with purified AA (ARASCO) and DHA (DHASCO) oils
[15,17]. However, the effect of HUFA-enriched oils more
commonly found in human diets, such as fish oil, have
not been explored in this novel mouse model.The objective of the current study was to determine
the differential effects of LA and ALA-enriched diets in
D6KO mice, with special focus on phospholipid PUFA
composition in the liver, the primary site of PUFA me-
tabolism. Secondly, to evaluate if adding a natural source
of HUFA (menhaden oil) to the diet can effectively re-
store the hepatic phospholipid HUFA content of D6KO
mice to levels seen in wild-type (WT) mice. Results of
this study further support the use of the D6KO model
for future studies aiming to determine the independent
effects of LA and ALA in ameliorating disease.
Results
Animals
Mean mouse body weight and food intake across all
treatment groups was not significantly different at the
end of the study (Table 1). Data derived from D6KO
groups were compared directly with WT groups, as het-
erozygous D6KO hepatic PL profiles did not differ from
WT liver PL profiles.
The production of D5D novel fatty acids and their
selective distribution in the liver
Based on previously published results [17], three peaks
corresponding to three Δ-5 desaturase (D5D) derived
fatty acids [20:3n6 (Δ7, 11, 14), 20:4n3 (Δ7, 11, 14, 17)
and 22:4n3 (Δ9, 13, 16, 19)] were found in the liver PL
fractions of D6KO mice fed LA-rich safflower oil (SF)
and LA+ALA-enriched soybean oil (SO) diets (Figure 2;
Figure 3). These three fatty acids were absent from all
three experimental diets, and were also absent in the
chromatographs of WT SF and SO fed mice. All three
novel fatty acids were found to be differentially distribu-
ted among the six PL fractions (PC, phosphatidylcholine;
PE, phosphatidylethanolamine; PS, phosphatidylserine;
PI, phosphatidylinositol; SM, sphingomyelin; Lyso-PC,
lyso-phosphatidylcholine). The PI fraction contained the
highest percentage of 20:3n6 (Δ7, 11, 14) (SO
=23.5 + 4.4%; SF = 30.6 + 1.6%) followed by the PS
(17.7 + 1.6%), PE (11.7 + 1.7%), SM (8.4 + 3.2%), Lyso-PC
(4.8 + 1.0%), and PC factions (4.1 + 0.6%) in SO-fed
D6KO mice; and followed by PS (20.9 + 2.2%), PE
(13.4 + 0.7%), PC (5.4 + 0.4%), SM (5.0 + 3.7%), and Lyso-
PC fractions (4.0 + 1.7%) in SF-fed D6KO mice
(Figure 3A). In the PI fraction of D6KO mice fed SF,
20:3n6 (Δ7, 11, 14) comprised almost a third of all fatty
acids, and in the PI fraction of SO-fed D6KO mice, this
novel fatty acid accounted for almost a fourth of total
fatty acids. 20:4n3 (Δ7, 11, 14, 17) and 22:4n3 (Δ9, 13,
16, 19) were also selectively distributed across PL frac-
tions, with the highest levels (relative to total fatty acids)
found in PE, PI and PS fractions (Figure 3B,C).
Trace amounts of all three novel fatty acids were
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Figure 1 A) The normal n-6 and n-3 fatty acid metabolic pathway. B) In the absence of Δ6 desaturase, Δ5 desaturase and elongases
metabolize LA and ALA to produce 3 novel fatty acids: 20:3(Δ7, 11, 14); 20:4(Δ7, 11, 14, 17), and 22:4(Δ9, 13, 16, 19).
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D6KO mice fed SO and SF (Figure 3). In the PC fraction
of MD-fed mice total D5D fatty acids composed
0.23 + 0.03% of total fatty acids; in comparison, the PC
fraction of SF and SO-fed mice contained 5.40 + 0.35%
and 4.77 + 0.69%, respectively. Similar trends were
observed in other PL fractions (Figure 3).
D5D fatty acids were not detected in WT mice fed SF
and SO diets, while PL fractions of WT mice fed MD
were all found to contain less than 1% D5D fatty acids.
Novel D5D fatty acid content of all PL fractions was sig-
nificantly different (p< 0.001) between WT and D6KO
mice fed either SO and SF, but% D5D fatty acids were
similar between WT and D6KO mice fed MD
(Figure 4F).
Comparison of liver LA and ALA levels across treatment
groups
LA content increased in most PL fractions of the three
D6KO treatment groups. In all PL fractions of SO-fed
D6KO mice LA content increased, and this increase was
significant in most fractions. In particular, in the PCTable 1 Mean weight gain and diet consumption




Safflower WT 7 6.2 ± 1.9 71.8 ± 4.6
KO 7 4.7 ± 1.7 70.16 ± 5.45
Soy WT 5 4.6 ± 2.2 71.3 ± 5.7
KO 3 5.1 ± 1.0 71.6 ± 6.0
Menhaden WT 4 6.6 ± 1.6 75.6 ± 4.1
KO 1 5.6 ± 1.9 78.9**
Note: *Weight gain is calculated from day on which mice were placed on
experimental diet until day mice were terminated. Diet consumption was
calculated from day mice were placed on experimental diet to Day 25.**Diet
consumption data available for one mouse.fraction of SO-mice LA content almost doubled from a
mean level of 21.12 + 3.38% in WT mice to 38.83 + 0.34%
in D6KO mice (p< 0.0001) (Figure 4A); while in the PE
fraction LA content showed a 3-fold increase. A similar
effect was seen between D6KO and WT mice fed SF diet
(Figure 4A). In contrast, in MD-fed mice, LA content
also increased in 5 of the 6 PL fractions, but this in-
crease was less than 2-fold in any fraction.
In all PL fractions of SF-fed and SO-fed mice ALA
content remained unchanged or increased. The increase
in ALA content was especially evident in SO-fed mice,
as the SO diet contains greater levels of ALA than the
SF diet. Across all PL fractions of D6KO mice on a SO
diet there was an approximately 3-fold or greater in-
crease in ALA content when compared with WT mice
fed SO-diets. In particular, the PC fraction of SO-fed
D6KO mice contained 1.75 +0.11% ALA compared with
only 0.61+ 0.10% in WT mice (p< 0.0001) (Figure 4B).
Unlike the results seen in SF and SO fed mice, ALA
levels remained constant or showed non-significant
decreases in MD-fed D6KO in comparison to their WT
counterparts.
Highly unsaturated fatty acids
Levels of AA were significantly lower in most PL frac-
tions of SF and SO-fed D6KO mice compared with their
WT counterparts (Figure 4C). There was also a small de-
crease in AA content in D6KO mice fed MD compared
with WT mice which did not reach significance in most
PL fractions.
EPA content remained similar or decreased in D6KO
mice fed SO or SF diets, while EPA levels actually
increased in MD-fed D6KO mice. After 4 weeks of feed-
ing D6KO mice a soy-based diet, EPA content decreased
non-significantly in the PC (Figure 4D) and PE fractions.









Figure 2 Novel Δ-5 desaturase (D5D) products are found in soybean oil (SO) fed D6KO mice. Representative chromatogram of the PC
fraction obtained from liver samples of SO fed D6KO sample (BLUE) superimposed on a MD-fed D6KO (GREEN). D5D products [20:3(Δ7,11,14); 20:4
(Δ7,11,14,17); 22:4(Δ9,13,16,19)] are noted in black, major HUFA are noted in red.
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and a similar increase was seen in most other fractions.
There was a decrease in DHA across all PL fractions
in both SF-fed and SO-fed D6KO mice. In the PL frac-
tions of MD-fed D6KO mice, DHA content remained
equivalent to WT mice, or declined (Figure 4E), but to a
lesser extent than was seen between D6KO and WT SF
or SO treatment groups.
N6/N3 ratio
The n6/n3 fatty acid ratio significantly increased 2–6
fold in the PC and PE fractions of SO and SF-fed D6KO
mice (SO WT ratio = 4.04 ± 0.74 vs. SO D6KO ratio
=15.44 ± 0.56; SF WT ratio = 25.29 ± 11.32 vs. SF D6KO
ratio = 69.66 ± 23.71; p = 0.05), while there was only a
slight non-significant increase in this ratio in MD-fed
mice (MD WT ratio = 1.59 ± 0.18 vs. MD D6KO
ratio = 1.89 ± 0.33).
Novel fatty acid distribution in serum lipid fractions
Serum phospholipid fractions were analyzed and it was
determined that all three novel D5D products were
present in the PL factions of D6KO mice. The distribu-
tion of serum phospholipid D5D fatty acids was similar
to the distribution found in liver PL fractions (Table 2).
Discussion
Change in liver lipid composition of D6KO mice fed
HUFA-deficient diets
The novel D6KO model has the potential to enhance our
fundamental understanding of the role of the essential
fatty acids ALA and LA in health and disease. However,careful examination of the phenotype under different ex-
perimental conditions is needed in order to ascertain its
potential utility and limitations. Previous research has
used diets containing n-6 and n-3 fatty acids from soy
[17], however, the effect of feeding only an LA-enriched
diet on the fatty acid composition of liver phospholipid
fractions in D6KO mice is currently unknown. Given that
n-6 and n-3 fatty acids share this same pathway, it is im-
portant to determine if feeding D6KO mice a diet
enriched in LA will result in a different hepatic fatty acid
profile than mice fed a diet containing both LA and ALA
[17]. Therefore, the first objective of the current study was
to characterize the liver phospholipid composition of
D6KO mice fed a diet rich in LA but void of ALA and
HUFAs.
In agreement with previous studies, three novel fatty
acid peaks were present in the phospholipid fractions of
D6KO mice. The first two fatty acids were identified as
20:3n6(Δ7, 11, 14) and 20:4n3(Δ7, 11, 14, 17) and are
the products of desaturation by D5D [17]. Additionally,
a third novel fatty acid, 22:4n3(Δ9, 13, 16, 19) was iden-
tified as a product of an elongase acting on 20:4n3(Δ7,
11, 14, 17). A diet rich in LA, such as a diet containing
safflower oil, results in the production of 20:3n6(Δ7, 11,
14), with trace quantities of the other two D5D fatty
acids in the tissues of D6KO mice. Feeding D6KO mice
a diet containing a source of ALA, such as soybean oil,
results in the production of all three novel D5D fatty
acids, with increased production of the two novel n-3
D5D products compared to a SF diet.
Mean weight gain and food intake was not signifi-






































































































Figure 3 (See legend on next page.)
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Figure 3 Preferential distribution of 3 novel D5D fatty acids among the liver phospholipid fractions of D6KO mice across dietary
treatment groups. A) Distribution of 20:3 (Δ7,11,14); B) distribution of 20:4 (Δ7,11,14,17); C) distribution of 22:4 (Δ9,13,16,19).
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The absence of any gross changes in the health status of
D6KO mice may also suggest that, over a short duration,
the provision of the parent PUFA LA and ALA may be





















































































Figure 4 Comparison of select fatty acid values found in the liver PC
genotypes and across dietary treatment groups: A) linoleic acid; B) α-
docosahexaenoic acid; F) total novel Δ-5 fatty acids. *indicates significa
between means determined by 2-way ANOVA. MD, menhaden oil, SF, saffleven as HUFA stores are depleted. Additionally, the
similar fatty acid profile of heterozygous D6KO mice
and WT mice suggests that even one functional copy of
the FADS2 gene is sufficient to maintain normal fatty






















































































fraction (shown as percent of total PC fatty acids) between
linolenic acid; C) arachidonic acid; D) eicosapentaenoic acid; E)
nt difference (p< 0.05) between D6KO and WT pairs; differences
ower; SO, soy.
Table 2 Novel D5D product composition in the serum phosphatidylcholine fraction
Menhaden Safflower Soy Menhaden Safflower Soy
Interaction
p- valueFatty Acid n = 4 n=7 n=5 n=4 n=7 n=3
WT KO
20:3(Δ7,11,14) 0.1 ± 0.09 0 0 0.1 ± 0.04 4.0 ± 1.74 a 2.6 ± 0.69 a <0.01
20:4(Δ7,11,14,17) 0.1 ± 0.07 0.1 ± 0.08 0.2 ± 0.05 0.1 ± 0.03 0.2 ± 0.06 0.1 ± 0.02 0.23
22:4(Δ9,13,16,19) 0 0 0 0 0 0.2 ± 0.05 a <0.01
Total D5D Products 0.2 ± 0.20 0.1 ±0.08 0.2 ± 0.05 0.2 ± 0.04 4.2 ± 1.80 a 2.9± 0.70 a <0.01
Note: Data were analyzed by 2-way ANOVA and are expressed as means +/− SD. Means with letters represent a significant difference (p< 0.05) from wild-type
values within a row.
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D6KO mice will differ from WT mice in response to
diets of varied fatty acid composition over a longer time
frame.
We confirmed that D6KO mice fed SF and SO diets
had considerably less EPA, DHA, and AA in all liver PL
fractions, as compared to WT mice. The n-6/n-3 fatty
acid ratio was also greatly increased in the liver tissues
of D6KO mice on SF and SO diets. The n-6/n-3 ratio is
one method of assessing tissue n-3 content relative to n-
6 fatty acid content [19]. A high n6/n3 ratio, such as the
~15:1 ratio of the average American diet, has been asso-
ciated with increased disease risk [20], while decreasing
this ratio to the recommended ~4:1 has been shown to
protect against disease [21,22]. While FADS2 loss of
function is rare in humans, several SNPs in the FADS2
gene have been discovered [23,24].Through the modifi-
cation of desaturase activity, certain FADS2 SNPs have
also been associated with disease risk [25,26]. The
results of this study then suggest that a decreased ability
to process ALA or LA via FADS2 polymorphisms [27]
or loss of function can lead to a higher PUFA ratio,
which may increase disease susceptibility. Additionally,
future studies can use the D6KO mouse as an suitable
model to study FADS2 SNPs which lead to decreased
D6D activity.
The selective distribution of novel fatty acids among
phospholipid fractions
The distribution of AA across phospholipid fractions is
tightly regulated, with each PL fraction containing varied
amounts of this n-6 fatty acid. In agreement with other
studies [9,28], we found that PI and PE fractions were
enriched in AA (data not shown). 20:3n6(Δ7, 11, 14), the
major D5D fatty acid, was shown to be selectively dis-
tributed among the PL fractions, composing almost a
third of PI fatty acids in SF-fed D6KO mice, and also
contributing largely to the PS and PE fatty acid pool.
Thus, the distribution of this fatty acid seems to follow a
similar distribution to AA. This could be associated with
selective PL remodeling seen with AA. For example, in a
previous study it was determined that while the initialincorporation of AA into PC was high, over time there
was a greater incorporation of AA into PE and PI [9].
This finding, and others [29,30] suggest that some
enzymes associated with PL remodeling show specificity
for AA. It is plausible that these same enzymes could
also have a similar affinity for 20:3n6(Δ7, 11, 14), causing
the distribution of this novel n-6 fatty acid to mimic the
selective distribution of AA across PL fractions.
Novel D5D fatty acids were also discovered in serum
phospholipids of D6KO mice, suggesting that once
formed, D5D fatty acids are not retained by the liver, but
make their way into the circulation. The effect of these
D5D fatty acids on extra-hepatic tissues is currently un-
known, but certainly could be a potential confounder.
A diet supplemented in preformed HUFA partially rescues
D6KO phenotype
The MD diet used in this study contained 3% (w/w) men-
haden oil and 7% safflower oil, amounting to approximately
0.4% (w/w) DHA, 0.04% AA, and 0.39% EPA (based on%
composition values in Table 3). Previous studies have
shown that 0.2% w/w DHA (DHASCO) supplementation is
sufficient to restore reproductive ability in D6KO mice [15],
while 0.4% w/w AA supplementation could prevent the
dermatitis and intestinal ulcers [17] otherwise seen in
D6KO mice fed HUFA deficient diets. Whether the
provision of only AA, EPA/DHA, or both n-6 and n-3
HUFA is sufficient for optimal rescue in these disease mod-
els requires further study. Towards understanding this im-
portant question, this study demonstrates the efficacy of
menhaden oil, a natural oil containing a mixture of n-6 and
n-3 HUFA, in rescuing the D6KO phenotype. This finding
is highly relevant and demonstrates the utility of menhaden
oil as an important control group in future investigations
using this model.
The addition of menhaden oil to the diet of D6KO mice
had a profound effect on PUFA levels in the PL fractions of
the liver. In contrast with D6KO mice on SF or SO diets,
D6KO mice fed MD diets had liver lipid profiles that
resembled their WT counterparts. While the PC fraction of
MD-fed D6KO mice did contain significantly more LA
compared with their WTcounterparts, the difference in LA
Table 3 Diet fatty acid composition
Fatty Acid 10% Safflower 10% Soy 3% fish + 7% safflower
n-6 (LA) n-3 (ALA) n-3 (HUFA)
14:0 0.2 0.2 2.6
16:0 6.3 10.8 10.4
16:1 0.1 0.2 3.2
18:0 2.6 4.3 3.0
18:1c9 14.6 21.1 12.2
18:1c11 0.7 1.5 1.4
18:2n6 73.6 52.8 53.7
18:3n6 0.0 0.0 0.1
18:3n3 0.2 6.9 0.6
18:4n3 0.0 0.0 1.1
20:0 0.4 0.4 0.4
20:1 0.1 0.3 0.2
20:2n6 0.0 0.0 0.2
20:3n6 0.1 0.0 0.1
20:4n6 0.0 0.0 0.4
20:3n3 0.0 0.0 0.1
20:5n3 0.0 0.0 3.9
22:0 0.3 0.6 0.4
22:1 0.1 0.2 0.1
22:4n6 0.0 0.0 0.1
22:5n6 0.0 0.0 0.2
22:5n3 0.0 0.1 0.8
24:0 0.2 0.2 0.1
22:6n3 0.0 0.0 4.0
24:1 0.0 0.0 0.3
sum 100% 100% 100%
Data are the means of analysis in duplicate and represent percentage of total
fatty acids in each diet.
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the SO and SF treatment groups.D6KO mice fed MD had
EPA levels which exceeded levels found in WT mice, while
DHA levels approached WT levels. ALA levels in MD-fed
D6KO and WT mice were nearly equivalent.
MD-fed D6KO mice also showed similar novel D5D
fatty acid profiles to the MD WT treatment group, pos-
sibly through the action of HUFA to stimulate and in-
hibit certain transcription factors. HUFA are well-known
inhibitors of SREBP-1c (sterol regulatory element bind-
ing protein-1c) which increase the transcription of D6D
[1,31,32] and D5D [33]. Studies have also concluded that
during EFA deficiency or starvation, PPARα (peroxisome
proliferator-activated receptor alpha) is activated
through the endogenous release of PUFA and up-regu-
lates the transcription of D6D and D5D [33,34]. Thus, in
conditions where HUFA are restricted, SREBP-1c and
PPARα,-two otherwise opposing enzymes- may act toincrease the transcription of D5D, resulting in increased
production of D5D fatty acid products. While gene ex-
pression was not specifically evaluated in the current
study, the study results support this hypothesis of D6D
and D5D regulation by PPARα and SREBP-1c, as the
hepatic PC fraction of MD-fed D6KO mice contained
less than 0.25% novel D5D fatty acids (of total fatty
acids), while SO and SF-fed D6KO mice PC fractions
contained between 4-6% novel fatty acids.
Conclusion and future directions
The present study demonstrates that the conversion of
LA and ALA toAA, EPA, and DHA is abolished in
D6KO mice. This is readily observed by the presence of
three novel D5D fatty acids in both liver and serum
phospholipid fractions. However, since the function of
these D5D fatty acids is unknown, their unwanted pro-
duction in D6KO mice represents a limitation of this
mouse model. The implications of this study demon-
strate that this limitation can be overcome through the
provision of dietary HUFAs, which inhibit the D5D me-
tabolism of ALA and LA. The major dietary n-3 s and
n-6 s consumed in a Western diet are ALA and LA, yet
minimal conversion of these fatty acids into their long
chain metabolites occurs in humans. Little is known
about the independent biological actions of LA and
ALA, thus with the aid of a fully characterized D6KO
model, future dietary studies can provide better insight




Heterozygous D6KO mice backcrossed to a C57BL/6
background [35], were transferred from University of
Illinois at Urbana-Champaign to the University of
Guelph where a colony of heterozygous mice was estab-
lished. Experimental mice consisting of D6KO and WT
mice were obtained from the breeding of harems con-
sisting of one heterozygous male and 2–3 females. Bree-
ders were fed standard laboratory mouse chow (Harlan
Tekad #9004), and pups were continued on this diet
until 28 days old. Mice were housed within ventilated
cages at 22°C in humidity-controlled environment on a
12 hour light: 12 hour dark cycle for the study duration.
At 21 days mice were weaned, and tail snips were
obtained for DNA extraction and PCR analysis to deter-
mine genotype [17]. PCR primers D6D WT forward
(CGGTGGGAGGAGGAGTAGAAGAC); D6D WT re-
verse (CCTCTCCCTGGTTACCTCCCTTC); D6D KO for-
ward (GCTATGACTGGGCACAACAG); and D6D KO
reverse (TTCGTCCAGATCATCCTGATC) were used.
Twenty-eight-day old homozygous D6KO and WT
mice were placed on one of three experimental diets
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Soy diet (SO; cat# D09072305) (n = 5 WT and 3 KO),
10% safflower diet (SF; cat# D04092701) (n = 7 WT and
7 KO), or 3% menhaden + 7% safflower diet (MD; cat#
D04092703) (n = 4 WT and 4 KO). Mice were fed experi-
mental diets for 28 days. At 56 days of age, the experi-
mental mice were euthanized using CO2, and final body
weights recorded. This investigation was approved by
the University of Guelph Animal Care Committee in ac-
cordance with the requirements of the Canadian Council
on Animal Care.
Fatty acid analysis
Upon termination, liver samples were collected, flash frozen
in liquid nitrogen, and stored at −80°C. For analysis, 0.1 g
of liver tissue was weighed and homogenized in 2.5 ml of
0.1 M potassium chloride. 10 ml chloroform (Fisher, Cat
#C298-4): methanol (Fisher, Cat #A452-4) solution (2:1 v/v)
was then added to the homogenized liver samples, accord-
ing to Folch et al [36]. Samples were vortexed, flushed with
nitrogen to prevent oxidation, and stored at 4°C overnight
[37]. Samples were then centrifuged at 577xg for 10 min-
utes to separate phases. The lipid-containing chloroform
layer was extracted into a pre-weighted acid-washed screw
cap test tube with Teflon lined cap, dried down under ni-
trogen gas, and weighed to determine the total mass of
lipids. 6 ml chloroform was added back into homogenized
liver sample, and the extraction process was repeated. Dried
lipid samples were reconstituted at 10 mg/ml chloroform
for thin layer chromatography (TLC).
Phospholipid fractions were then separated using TLC.
Briefly, silica H plates (VWR 5721–7) were activated by
heating at 100°C for 1 hour. 100μl of each liver lipid sam-
ple were spotted along 2 cm lanes scored onto the acti-
vated plates. Samples were run alongside known
phospholipid standards for 2.5 hours in chloroform/
methanol/ 2-propanol (Fisher A416-1) /KCl (0.25%w/v)/
triethylamine (Sigma Cat# CT0886) (30:9:25:6:18). Frac-
tions were visualized using 0.1% 8-anilino-1-naphthalene
sulfonic acid (w/v) (Fluka # 10417) under UV light. Bands
corresponding to PC, PE, PS, PI, SM and lyso-PC were
identified and individually scraped into acid washed test
tubes already containing 1.0μl (PC) or 0.1μl (PE, PS, PI,
SM, Lyso PC) 17:0 FFA as an internal standard and 2 ml
hexane. 2 ml 14% boron triflouride-methanol (Sigma, cat
#B1252) was next added, and samples were methylated for
1.5 hours at 100C. Samples were allowed to cool (RT),
then 2 ml distilled water was added to each sample to halt
methylation, and samples were centrifuged at 577× g for
10 minutes. The hexane layer containing methylated fatty
acids was extracted into a gas chromatography vials. Sam-
ples were then dried down under a gentle stream of nitro-
gen gas and reconstituted in in 30μl (100μl for PC) hexane
in glass gas chromatography inserts [37].PL fatty acid methyl esters were quantified using an
Agilent 6890 N gas chromatograph equipped with a
flame ionized detector and separated on a Supelco SP-
2560 fused silica capillary column (100 m, 0.2 μm film
thickness, 0.25 mm i.d.; Sigma cat #24056 ) [37]. Hydro-
gen was used as the carrier gas and set at a constant
flow rate of 30 mL/min. Samples were injected in split-
less mode. The injector and detector ports were set at
250°C. Fatty acid methyl esters were eluted through the
column using temperature program of: 0.2 min at 60°C,
then increasing 13°C/min until a temperature of 170°C
was reached. 170°C was held for 4 min, then increased
6.5°C/min to 175°C, increased 2.6°C/min to 185°C,
increased 1.3°C/min to 190°C, and finally increased
13°C/min to 240°C and held at this temperature for
13 min. The run time per sample was 37.77 min. Fatty
acids were identified by comparing peak retention times
with those of a known standard (Nu-Chek-Prep, Elysian,
MN). Fatty acid peak areas were determined using
EZChrom Elite software (Version 3.3.2). Fatty acid values
were expressed as percent area in each PL fraction.
Serum lipid fraction analysis was carried out under
the same conditions as liver tissue samples above
using 50 μl serum. Briefly, serum lipids were double
extracted, dried down and reconstituted in 150 μl
chloroform. 100 μl of reconstituted lipid sample was
spotted onto an activated TLC H-plate, and phospho-
lipid bands were scraped, methylated for an hour, and
analyzed using Agilent 7890 gas chromatograph under
the same temperature program as liver samples.
Statistical analysis
Data were analyzed using SAS (v. 9.1) statistical soft-
ware. 2-way analysis of variance test was performed
on data, followed by Tukey post-hoc tests on main
effects when the interaction term was not significant;
Least Squares Means was used when interaction
values were significant. Statistical significance was set
at p< 0.05.
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